Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 277.90M | 232.34M | 183.03M | 90.09M | 14.56M |
Gross Profit | 181.72M | 163.76M | 124.33M | 54.95M | 7.09M |
EBITDA | 21.87M | -68.50M | -167.31M | -183.34M | -206.19M |
Net Income | -13.62M | -94.01M | -200.38M | -195.82M | -216.08M |
Balance Sheet | |||||
Total Assets | 1.21B | 1.20B | 1.31B | 1.50B | 773.63M |
Cash, Cash Equivalents and Short-Term Investments | 713.72M | 721.14M | 870.12M | 1.22B | 632.42M |
Total Debt | 35.75M | 36.38M | 50.69M | 41.94M | 24.69M |
Total Liabilities | 144.00M | 125.60M | 147.08M | 132.10M | 82.60M |
Stockholders Equity | 1.06B | 1.08B | 1.17B | 1.37B | 681.37M |
Cash Flow | |||||
Free Cash Flow | -8.39M | -137.72M | -304.01M | -260.33M | -90.42M |
Operating Cash Flow | -3.23M | -88.41M | -266.77M | -205.85M | -74.81M |
Investing Cash Flow | 10.80M | -125.45M | 44.84M | -161.10M | -4.53M |
Financing Cash Flow | -12.38M | -21.48M | -24.75M | 821.25M | 686.22M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
61 Neutral | HK$1.96B | ― | -1.28% | ― | 17.45% | 85.71% | |
58 Neutral | £4.95B | 6.56 | -62.36% | 103.85% | 34.03% | 6.31% | |
― | €593.03M | ― | -10.43% | ― | ― | ― | |
69 Neutral | HK$8.42B | 35.78 | 6.49% | ― | 0.87% | -18.05% | |
52 Neutral | HK$3.06B | ― | -2.19% | ― | 5.32% | 89.43% | |
― | HK$2.76B | ― | -3.13% | ― | ― | ― | |
46 Neutral | HK$1.27B | ― | -27.82% | ― | -6.12% | 0.43% |
Shanghai HeartCare Medical Technology Corporation Limited has announced the closure of its H Share register of members from July 30, 2025, to August 29, 2025, to determine shareholders eligible to attend and vote at the 2025 second extraordinary general meeting scheduled for August 29, 2025. This move is significant for shareholders as it dictates the timeline for share transfers and eligibility to participate in the company’s decision-making process during the EGM.
The most recent analyst rating on (HK:6609) stock is a Buy with a HK$25.60 price target. To see the full list of analyst forecasts on Shanghai Heartcare Medical Technology Corp. Ltd. Class H stock, see the HK:6609 Stock Forecast page.
Shanghai HeartCare Medical Technology Corp. Ltd. successfully held its 2024 Annual General Meeting (AGM) and Extraordinary General Meeting (EGM) on May 26, 2025, where all proposed resolutions were passed by poll. The meetings were conducted in compliance with the Company Law of the PRC and the Articles of Association, with significant shareholder participation, indicating robust governance and stakeholder engagement.
The most recent analyst rating on (HK:6609) stock is a Buy with a HK$25.60 price target. To see the full list of analyst forecasts on Shanghai Heartcare Medical Technology Corp. Ltd. Class H stock, see the HK:6609 Stock Forecast page.
Shanghai Heartcare Medical Technology Corp. Ltd. has announced an Extraordinary General Meeting (EGM) to be held on May 26, 2025, to discuss and potentially approve the 2025 H Share Incentive Scheme and related resolutions. This initiative is aimed at enhancing shareholder value and aligning the interests of the company’s management with those of its shareholders, potentially impacting its market positioning and stakeholder engagement.
Shanghai HeartCare Medical Technology Corporation Limited has announced a proposal to adopt the 2025 H Share Incentive Scheme. The scheme aims to attract and retain key participants, align their interests with the company’s goals, and enhance long-term performance. The adoption of the scheme is subject to shareholder approval at an upcoming extraordinary general meeting, and it is expected to positively impact the company’s operational and strategic objectives.